Volixibat - Mirum Pharmaceuticals
Alternative Names: LUM-002; SAR-548304; SHP-626; Volixibat - Takeda; Volixibat potassiumLatest Information Update: 14 Oct 2024
At a glance
- Originator sanofi-aventis
- Developer Mirum Pharmaceuticals; Sanofi; Shire
- Class Anti-inflammatories; Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Primary biliary cirrhosis
- Phase II Intrahepatic cholestasis; Primary sclerosing cholangitis
- No development reported Cholestasis
- Discontinued Hypercholesterolaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 10 Oct 2024 Volixibat - Mirum Pharmaceuticals receives Breakthrough Therapy status for Primary biliary cirrhosis in USA
- 17 Jul 2024 Phase-II clinical trials in Primary sclerosing cholangitis in Argentina, Belgium, Italy, Netherlands (PO) (NCT04663308)
- 03 Jul 2024 Phase-II clinical trials in Primary biliary cirrhosis in Spain (PO) (NCT05050136)